|
Image Analysis: A Vital Tool in Drug Discovery
Amanda Lowe, Senior Vice President and Andreas Schonau, Chief Scientific Officer of Visiopharm, a solution provider company at the marcus evans Discovery Summit 2015, on how quantitative digital pathology can enhance the drug discovery process.
LONDON, Sep 08, 2015 - (ACN Newswire) - "We are at a very exciting time when it comes to digital pathology and image analysis as we are now seeing the first pathology laboratories use Visiopharm image analysis for in-vitro diagnostics. This is a huge step forward and a step that will benefit not only laboratories and patients, but also the pharmaceutical and diagnostic industry as it will enable more widespread use of quantitative measures that have so far been limited to high-end discovery and research facilities," says Andreas Schonau, Chief Scientific Officer, Visiopharm.
Visiopharm, is a solution provider company, attending the marcus evans Discovery Summit 2015 in Las Vegas, Nevada, September 21-22.
- What knowledge is missing from drug discovery today?
Amanda: The way that the knowledge is generated is not always effective. A lot of the knowledge created around, for example target validation or the testing of lead compounds, is often very subjective and qualitative.
Image analysis enables drug companies to eliminate subjectivity, and provide verifiable, quantitative results. It can also reduce inter and intra reader variability by creating standardized best practices for obtaining important information about tissue samples. Important decisions can then confidently be made by maximizing the scientific study of tissue in a measurable and reproducible way.
- How can pharmaceutical companies improve their discovery process?
Amanda: Most importantly, the quality of scientific data must be reproducible and verifiable. Data must lead to confident, go or no-go decisions around the drug development process.
The process should also be done in a productive and cost effective way by making accurate decisions to achieve more results, in less time. That is where quantitative digital pathology, whole slide scanners and image analysis software, can really make a difference. Quantitative digital pathology is the right innovation to drive up productivity, control costs, and provide the scientific data required to make confident decisions.
Andreas: Image analysis can improve the discovery phase by providing metrics that cannot be achieved in any other way. It supports testing of samples in ways that are too complicated to be achieved and reproduced by the human eye. It also leads to workflow improvement, by allowing the scientists to analyze more samples and get more accurate results out of the available material, thereby reducing the risk of failed studies.
Digital pathology and image analysis are tools that support the sharing of images, methods and results in a more non-subjective way. It promotes collaboration between academia and pharmaceutical sectors and helps them to speak the same language, alleviating misunderstandings and eliminate unexpected interpretations.
- What is the key in evolving research into clinical practice?
Andreas: Bridging the gap between research and clinical practice is an everyday challenge for drug development companies. Tools and methods for drug research and discovery have to be very open and flexible, yet quantitative and precise, to accommodate the many questions and validate the many hypotheses that are investigated during the early phases of drug development.
In clinical practice, the demands change, and tools have to be standardized, easy to use and very robust in order to meet the requirements and challenges of analyzing real patient samples in a busy routine laboratory.
Image analysis has been used in research for years but now the technological development of image analysis software and whole slide scanners is getting to a stage where it not only offers opportunities for significant value creation in pharma research, but also allows for implementation in routine clinical diagnostics. Quantitative Digital Pathology is the strong bridge that will span the gap between research and clinical practice, while ensuring high quality, consistent data and workflow improvements at the same time.
About the Discovery Summit 2015
The Discovery Summit is the premium forum bringing senior drug discovery executives and solution providers together. As an invitation-only event taking place behind closed doors, the Summit offers an intimate environment for a focused discussion on state of the art solutions, technology and information shaping the future of the industry. Taking place at Red Rock Resort & Spa, Las Vegas, Nevada, USA, September 21-22, 2015, the Summit includes presentations on target discovery and validation, collaboration between big pharma, academia and non profits, identifying new methods for drug screening and strategies to gaining the best ROI.
For more information please send an email to press@marcusevanscy.com or visit the event website at http://discovery.marcusevans-summits.com/
marcus evans group - life sciences / pharma sector portal - www.marcusevans.com/reviews/sciences
The Pharma Network - marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
- LinkedIn: www.linkedin.com/groups?gid=3529112&trk=myg_ugrp_ovr
- YouTube: www.youtube.com/MarcusEvansPharma
- Twitter: www.twitter.com/meSummitsPharma
- SlideShare: www.slideshare.net/MarcusEvansPharma
Please note that the Summit is a closed business event and the number of participants strictly limited.
About Visiopharm
Over the past 15 years, Visiopharm image analysis software has become the preferred Quantitative Digital Pathology solution for scientists and pathologists all over the world. Biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and hospital diagnostic pathology labs partner with Visiopharm to reveal answers to the toughest scientific questions surrounding biomarker discovery, companion diagnostics, and the characterization of physiological structures in tissue. Visiopharm's software has been featured in over 800 scientific publications and is compatible with leading slide scanners and data management software. www.visiopharm.com
Contact:Luzdary Hammad,
Press Manager, marcus evans, Summits Division
Tel: +357 22 849 385
Email: press@marcusevanscy.com
Source: marcus evans Summits
Sectors: Daily Finance, Daily News
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network. |
Latest Release
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
| 
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
| 
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
| 
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
| 
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
| 
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
| 
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
| 
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
| 
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
| 
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
| 
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
| 
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
|
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
| 
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
|
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
| 
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
|
More Latest Release >>
|